Wordt geladen...
Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years following immunochemotherapy, 30-40% of patients will experience a relapse or a refractory disease, thereby exhibiting a poor prog...
Bewaard in:
| Gepubliceerd in: | Mol Clin Oncol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
D.A. Spandidos
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7416618/ https://ncbi.nlm.nih.gov/pubmed/32789017 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2103 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|